BIOA NASDAQ
BioAge Labs, Inc.
1W: -10.6%
1M: -8.8%
3M: -18.4%
YTD: +30.5%
1Y: +307.3%
$16.61
-0.13 (-0.78%)
Weekly Expected Move ±9.6%
$14
$16
$18
$19
$21
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.90
Bullish
1 bullish
0 neutral
0 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (30)
Is BioAge Labs, Inc. (BIOA) a Top Longevity Biotech Stock to Watch After New Analyst Coverage?
BioAge Labs GAAP EPS of -$0.52, revenue of $2.8M
[10-Q] BioAge Labs, Inc. Quarterly Earnings Report - Stock Titan
BioAge Labs Reports First Quarter 2026 Financial Results and Provides Business Updates
BioAge Labs Reports First Quarter 2026 Financial Results and Provides Business Updates
BioAge to Host R&D Day Focused on NLRP3 Inhibition on May 8, 2026
Has Amarin (AMRN) Outpaced Other Medical Stocks This Year?
BioAge Labs Stock Gains After Positive Early Data And Pipeline Plans
Wall Street Analysts Predict an 183.67% Upside in BioAge Labs, Inc. (BIOA): Here's What You Should Know
Fastenal, Replimune Group, Children's Place And Other Big Stocks Moving Lower In Monday's Pre-Market Session
BioAge Labs (NASDAQ:BIOA) Stock Price Down 6% – Should You Sell?
Brokerages Set BioAge Labs, Inc. (NASDAQ:BIOA) Target Price at $46.25
Is Amgen (AMGN) Outperforming Other Medical Stocks This Year?
BioAge Labs (NASDAQ:BIOA) Shares Gap Up – Should You Buy?
This Honeywell Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
BioAge Labs GAAP EPS of -$2.24 beats by $0.08, revenue of $8.99M beats by $1.88M
BioAge Labs Reports Full Year 2025 Financial Results and Provides Business Updates from the Fourth Quarter of 2025
BioAge Labs Reports Full Year 2025 Financial Results and Provides Business Updates from the Fourth Quarter of 2025
Analysts Set BioAge Labs, Inc. (NASDAQ:BIOA) PT at $45.00
Small-Cap healthcare stocks ranked by quant ratings after earnings season
BioAge Labs, Inc. (NASDAQ:BIOA) Short Interest Update
Top Quant ranked small cap stocks with negative EPS surprises
BioAge Announces Pricing of Upsized $115.0 Million Public Offering
BioAge Announces Proposed Public Offering
BioAge Announces Indication Expansion for Oral NLRP3 Inhibitor BGE-102, with Plans to Initiate Phase 1b/2a Proof-of-Concept Clinical Trial in Patients with Diabetic Macular Edema in Mid-2026
BioAge Rockets As It Takes On Eli Lilly's Takeover Play, Ventyx Bio
BioAge Announces Additional Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor, Demonstrating Potential for Best-in-Class hsCRP Reduction in Participants with Elevated Cardiovascular Risk
2 Reasons I Wouldn't Touch BioAge Labs Stock With a 10-Foot Pole
BioAge Announces Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor
BioAge Labs to Present at Piper Sandler 37th Annual Healthcare Conference